Safety and Efficacy of Quavonlimab With Pembrolizumab in First-Line Advanced Non–Small Cell Lung Cancer
abstract
This abstract is available on the publisher's site.
Access this abstract now Full Text Available for ClinicalKey SubscribersBACKGROUND
Quavonlimab (MK-1308), a novel anti-CTLA-4 antibody, in combination with pembrolizumab was investigated in a phase I study.
PATIENTS AND METHODS
Dose-escalation phase (DE): patients with advanced/metastatic solid tumors received an initial flat dose of quavonlimab as monotherapy (25 mg [cohort 1], 75 mg [cohort 2], or 200 mg [cohort 3]) followed by 4 treatments of the same quavonlimab dose plus pembrolizumab Q3W. Dose-confirmation phase (DC): patients with stage IIIB/IV NSCLC received first-line quavonlimab (25 mg Q3W [arm A], 25 mg Q6W [arm B], 75 mg Q6W [arm C], or 75 mg Q3W [arm E]) plus pembrolizumab. Primary objectives were safety and tolerability and establishment of the recommended phase II dose (RP2D) of quavonlimab when used with pembrolizumab. ORR was a secondary end point. Efficacy based on PD-L1 expression, TMB, and changes in circulating CD4+/CD8+ cells were exploratory end points.
RESULTS
Thirty-nine patients were enrolled in DE (n=14 [cohort 1]; n=17 [cohort 2]; n=8 [cohort 3]) and 134 in DC (n=40 [arm A]; n=40 [arm B]; n=40 [arm C]; n=14 [arm E]). Maximum-tolerated dose was not reached. Grade 3-5 treatment-related AEs occurred in 0%, 23.5%, and 75.0% of patients in DE cohorts 1, 2, and 3, respectively, and 35.0%, 30.0%, 35.0%, and 57.1% of patients in DC arms A, B, C, and E, respectively. Efficacy was observed at all dose levels/schedules in patients with NSCLC. ORRs were 40.0% (95% CI, 24.9-56.7; arm A), 37.5% (95% CI, 22.7-54.2; arm B), 27.5% (95% CI, 14.6-43.9; arm C), and 35.7% (95% CI, 12.8-64.9; arm E). PD-L1 expression and total number of circulating CD4+ cells correlated with ORR.
CONCLUSIONS
Quavonlimab 25 mg Q6W plus pembrolizumab demonstrated similar efficacy and a better safety profile among all quavonlimab doses/schedules evaluated; this regimen was the chosen RP2D.
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts
Additional Info
Safety and Efficacy of Quavonlimab, a Novel Anti–CTLA-4 Antibody (MK-1308), in Combination With Pembrolizumab in First-Line Advanced Non–Small Cell Lung Cancer
Ann. Oncol 2020 Dec 01;[EPub Ahead of Print], R Perets, J Bar, DW Rasco, MJ Ahn, K Yoh, DW Kim, A Nagrial, M Satouchi, DH Lee, DR Spigel, D Kotasek, M Gutierrez, J Niu, S Siddiqi, X Li, J Cyrus, A Chackerian, A Chain, RA Altura, BC ChoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.